Last reviewed · How we verify
Continuation of boosted PI — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Continuation of boosted PI (Continuation of boosted PI) — Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Continuation of boosted PI TARGET | Continuation of boosted PI | Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Continuation of boosted PI CI watch — RSS
- Continuation of boosted PI CI watch — Atom
- Continuation of boosted PI CI watch — JSON
- Continuation of boosted PI alone — RSS
Cite this brief
Drug Landscape (2026). Continuation of boosted PI — Competitive Intelligence Brief. https://druglandscape.com/ci/continuation-of-boosted-pi. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab